GHK-Cu is regulated as a cosmetic ingredient, not an approved drug for therapeutic claims, and regulatory status of both the peptide and needling devices varies by jurisdiction
The medication works by: Enhancing insulin secretion in a glucose-dependent manner, reducing the risk of hypoglycemia Suppressing glucagon release when blood glucose levels are elevated Slowing gastric emptying , which prolongs satiety and reduces appetite Acting on central appetite regulation in the hypothalamus to decrease food intake Zepbound is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 2.5 mg and gradually titrated upward (5 mg, 7.5 mg, 10 mg, 12.5 mg, to a maximum of 15 mg) based on individual tolerance and therapeutic response
A Phase 2 trial published in JCEM demonstrated sustained GH elevation (mean 60% increase) and IGF-1 increases of 4090% maintained across 12 months of daily dosing
Notice whats missing from all these studies
Wind-induced skin aging: the role of cutaneous antioxidants in the pathogenesis of skin aging